Blockchain Registration Transaction Record

Quantum BioPharma Advances MS Treatment with UK Regulatory Submission

Quantum BioPharma submits Lucid-MS, a groundbreaking MS treatment, to UK's ILAP program, aiming to fast-track patient access to innovative therapies.

Quantum BioPharma Advances MS Treatment with UK Regulatory Submission

This news is pivotal for individuals affected by multiple sclerosis and the broader medical community, as it signifies progress towards a novel treatment that could halt or reverse the disease's progression. Quantum BioPharma's engagement with the ILAP program not only accelerates the potential availability of Lucid-MS but also exemplifies how strategic regulatory collaborations can bring innovative therapies to patients faster. For investors, this development highlights Quantum BioPharma's growth potential and its commitment to addressing unmet medical needs through cutting-edge science.

BlockchainDetails
Contract Address0xeA2912a8DA1CD48401b10cB283585874d98098F4
Transaction ID0xdae7d524a7f095bcd8e35e193916e03dcaa532649b78b624cb4ba43bf5de2954
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital Fingerprintirisl9sf-199a4aaad6bd3dc66fa764470633836e